课题基金 / 基金详情

BRAIN AS TARGET FOR ANTISENSE PEPTIDE NUCLEIC ACID DRUGS

BRAIN AS TARGET FOR ANTISENSE PEPTIDE NUCLEIC ACID DRUGS
脑作为反义肽核酸药物的靶标
批准号:
6392626
负责人:
ELLIOTT RICHELSON
金额:
$32.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-08-01 至 2002-07-31

项目摘要

项目成果

ELLIOTT RICHELSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Applicant's Abstract) The goal of the proposed research is to characterize in rat the pharmacokinetics and pharmacodynamics of three antisense polyamide ("peptide") nucleic acids (PNAs) directed toward three different proteins in rat brain: the neurotensin receptor subtype 1 (NTR1), the morphine receptor subtype (MOR1), and the serotonin transporter (SERT). The long term goal of this research is to develop PNAs as antisense and antigene drugs to treat a variety of diseases, especially those affecting brain. In different experiments, different PNAs (either in unlabeled or in radioactively-labeled or fluorescently-labeled forms) will be administereed to rats by intravenous, intraperitoneal, or oral routes. From measurement of concentrations of PNAs in blood over time, pharmacokinetic variables, including absolute bioavailability of PNAs by the oral route, will be determined. The kinetics of entry of these PNAs into brain (as well as other organs) and their distributions within the brain will also be determined by various techniques, including histological. The kinetics of entry into brain will be correlated with the time course for the onset of and the recovery from their functional effects from behavioral, physiological, biochemical, and molecular biological experiments. Behavioral studies will measure antinociception (NTR1 and MOR1); physiological studies, hypothermia (NTR1); biochemical studies, binding sites for NTR1, MOR1, and SERT, as well as brain levels of serotonin and its metabolite, and molecular biological studies, levels of mRNA for each targeted protein. This research represents the initial studies that might lead to viable antisense and antigene therapies for many types of diseases.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/s0006-2952(01)00698-0
发表时间: 2001
期刊: Biochemical pharmacology
影响因子: 5.8
作者: [Tyler-McMahon,BM, Stewart,JA, Jackson,J, Bitner,MD, Fauq,A, McCormick,DJ, Richelson,E]
通讯作者: Richelson,E
Intraperitoneal injection of antisense peptide nucleic acids targeted to the mu receptor decreases response to morphine and receptor protein levels in rat brain.
腹腔注射针对 mu 受体的反义肽核酸可降低大鼠脑中对吗啡和受体蛋白水平的反应。
DOI: 10.1016/s0006-8993(01)02511-2
发表时间: 2001
期刊: Brain research
影响因子: 2.9
作者: [McMahon,BM, Stewart,JA, Jackson,J, Fauq,A, McCormick,DJ, Richelson,E]
通讯作者: Richelson,E
NT69L: a potential, novel antischizophrenic drug
  • 批准号:
    7595117
  • 项目类别:
  • 资助金额:
    $28.23万
  • 财政年份:
    2006
  • 负责人:
    ELLIOTT RICHELSON
  • 依托单位:
NT69L: a potential, novel antischizophrenic drug
  • 批准号:
    7409750
  • 项目类别:
  • 资助金额:
    $28.23万
  • 财政年份:
    2006
  • 负责人:
    ELLIOTT RICHELSON
  • 依托单位:
NT69L: a potential, novel antischizophrenic drug
  • 批准号:
    7093854
  • 项目类别:
  • 资助金额:
    $28.27万
  • 财政年份:
    2006
  • 负责人:
    ELLIOTT RICHELSON
  • 依托单位:
NT69L: a potential, novel antischizophrenic drug
  • 批准号:
    7676559
  • 项目类别:
  • 资助金额:
    $11.42万
  • 财政年份:
    2006
  • 负责人:
    ELLIOTT RICHELSON
  • 依托单位:
海外基金